These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 32704352)
1. Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19. Potter H; Boyd TD; Clarke P; Pelak VS; Tyler KL F1000Res; 2020; 9():345. PubMed ID: 32704352 [TBL] [Abstract][Full Text] [Related]
2. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Bonaventura A; Vecchié A; Wang TS; Lee E; Cremer PC; Carey B; Rajendram P; Hudock KM; Korbee L; Van Tassell BW; Dagna L; Abbate A Front Immunol; 2020; 11():1625. PubMed ID: 32719685 [TBL] [Abstract][Full Text] [Related]
3. Treatment with Granulocyte-Macrophage Colony-Stimulating Factor Reduces Viral Titers in the Brains of West Nile Virus-Infected Mice and Improves Survival. Stonedahl S; Leser JS; Clarke P; Potter H; Boyd TD; Tyler KL J Virol; 2023 Mar; 97(3):e0180522. PubMed ID: 36802227 [TBL] [Abstract][Full Text] [Related]
4. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Lang FM; Lee KM; Teijaro JR; Becher B; Hamilton JA Nat Rev Immunol; 2020 Aug; 20(8):507-514. PubMed ID: 32576980 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of B-1a Cells in COVID-19. Aziz M; Brenner M; Wang P Shock; 2020 Nov; 54(5):586-594. PubMed ID: 32604223 [TBL] [Abstract][Full Text] [Related]
7. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial. Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663 [TBL] [Abstract][Full Text] [Related]
9. The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice. Ahmed MM; Wang AC; Elos M; Chial HJ; Sillau S; Solano DA; Coughlan C; Aghili L; Anton P; Markham N; Adame V; Gardiner KJ; Boyd TD; Potter H Neurobiol Dis; 2022 Jun; 168():105694. PubMed ID: 35307513 [TBL] [Abstract][Full Text] [Related]
10. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Astuti I; Ysrafil Diabetes Metab Syndr; 2020; 14(4):407-412. PubMed ID: 32335367 [TBL] [Abstract][Full Text] [Related]
11. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300 [TBL] [Abstract][Full Text] [Related]
12. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Rao L; Xia S; Xu W; Tian R; Yu G; Gu C; Pan P; Meng QF; Cai X; Qu D; Lu L; Xie Y; Jiang S; Chen X Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27141-27147. PubMed ID: 33024017 [TBL] [Abstract][Full Text] [Related]
14. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996 [TBL] [Abstract][Full Text] [Related]
15. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets? Sallenave JM; Guillot L Front Immunol; 2020; 11():1229. PubMed ID: 32574272 [TBL] [Abstract][Full Text] [Related]
16. The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm? Bellinvia S; Edwards CJ; Schisano M; Banfi P; Fallico M; Murabito P Inflamm Res; 2020 Aug; 69(8):757-763. PubMed ID: 32468151 [TBL] [Abstract][Full Text] [Related]
17. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM Front Immunol; 2020; 11():1979. PubMed ID: 32973803 [TBL] [Abstract][Full Text] [Related]
18. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. Zhao Y; Qin L; Zhang P; Li K; Liang L; Sun J; Xu B; Dai Y; Li X; Zhang C; Peng Y; Feng Y; Li A; Hu Z; Xiang H; Ogg G; Ho LP; McMichael A; Jin R; Knight JC; Dong T; Zhang Y JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32501293 [TBL] [Abstract][Full Text] [Related]
20. Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. Nowill AE; de Campos-Lima PO J Immunol; 2020 Nov; 205(10):2566-2575. PubMed ID: 32958687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]